Financial News
New Crypto Pepeto Passes $8.25M While Dogecoin Price Prediction Heats Up and Elon Musk Confirms X Money Goes Live in April
Dubai, UAE, March 21, 2026 (GLOBE NEWSWIRE) -- Pepeto just cleared $8.25 million in presale and every signal around this new crypto is lining up in a way the market has witnessed only twice, once with Dogecoin and once with Shiba Inu, both just before Elon Musk turned them into global headlines.
All
Basic Materials
Communication Services
Consumer Cyclical
Consumer Defensive
Energy
Financial Services
Healthcare
Industrials
Real Estate
Technology
Utilities
Macro
All Sentiment
Bullish
Neutral
Bearish
2,258 articles
Wheaton Precious Metals Corp. $WPM Position Increased by CIBC Private Wealth Group LLC
CIBC Private Wealth Group LLC grew its position in Wheaton Precious Metals Corp. (NYSE:WPM – Free Report) by 15.9% in the 3rd quarter,...
Microbot Medical Inc. $MBOT Shares Purchased by CIBC Private Wealth Group LLC
CIBC Private Wealth Group LLC raised its position in Microbot Medical Inc. (NASDAQ:MBOT – Free Report) by 137.6% in the third quarter,...
Central Pacific Bank Trust Division Makes New $789,000 Investment in BridgeBio Pharma, Inc. $BBIO
Central Pacific Bank Trust Division bought a new stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) during the fourth quarter,...
Central Pacific Bank Trust Division Buys New Holdings in Edwards Lifesciences Corporation $EW
Central Pacific Bank Trust Division purchased a new position in Edwards Lifesciences Corporation (NYSE:EW – Free Report) in the 4th quarter,...
Central Pacific Bank Trust Division Takes $952,000 Position in Astrazeneca Plc $AZN
Central Pacific Bank Trust Division purchased a new position in Astrazeneca Plc (NYSE:AZN – Free Report) in the 4th quarter, according to the...
Central Pacific Bank Trust Division Buys New Holdings in Edwards Lifesciences Corporation $EW
Central Pacific Bank Trust Division purchased a new position in Edwards Lifesciences Corporation (NYSE:EW – Free Report) in the 4th quarter,...
Central Pacific Bank Trust Division Takes $952,000 Position in Astrazeneca Plc $AZN
Central Pacific Bank Trust Division purchased a new position in Astrazeneca Plc (NYSE:AZN – Free Report) in the 4th quarter, according to the...
AnaptysBio (NASDAQ:ANAB) Sees Unusually-High Trading Volume – Should You Buy?
AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) saw unusually-strong trading volume on Friday . Approximately 528,569 shares changed hands...
Eton Pharmaceuticals (NASDAQ:ETON) Sees Strong Trading Volume on Analyst Upgrade
Shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON – Get Free Report) saw unusually-strong trading volume on Friday after Zacks Research...
Aventura Private Wealth LLC Takes $2.14 Million Position in AbbVie Inc. $ABBV
Aventura Private Wealth LLC purchased a new position in AbbVie Inc. (NYSE:ABBV – Free Report) during the fourth quarter, according to its most...
Aventura Private Wealth LLC Takes $2.14 Million Position in AbbVie Inc. $ABBV
Aventura Private Wealth LLC purchased a new position in AbbVie Inc. (NYSE:ABBV – Free Report) during the fourth quarter, according to its most...
Doximity, Inc. $DOCS Shares Acquired by Allworth Financial LP
Allworth Financial LP increased its stake in Doximity, Inc. (NYSE:DOCS – Free Report) by 369.7% in the third quarter, according to the company...
Halozyme Therapeutics, Inc. $HALO Shares Purchased by Allworth Financial LP
Allworth Financial LP lifted its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 322.5% during the third...
Halozyme Therapeutics, Inc. $HALO Shares Purchased by Allworth Financial LP
Allworth Financial LP lifted its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 322.5% during the third...
AIA Group Ltd Takes $617,000 Position in Quest Diagnostics Incorporated $DGX
AIA Group Ltd bought a new position in Quest Diagnostics Incorporated (NYSE:DGX – Free Report) during the third quarter, according to the...
AIA Group Ltd Takes $617,000 Position in Quest Diagnostics Incorporated $DGX
AIA Group Ltd bought a new position in Quest Diagnostics Incorporated (NYSE:DGX – Free Report) during the third quarter, according to the...
AIA Group Ltd Purchases Shares of 1,299 United Therapeutics Corporation $UTHR
AIA Group Ltd acquired a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR – Free Report) in the 3rd quarter, according to...
Solid Biosciences (NASDAQ:SLDB) Shares Gap Up After Earnings Beat
Solid Biosciences Inc. (NASDAQ:SLDB – Get Free Report) shares gapped up before the market opened on Friday following a better than expected...
Exclusive: Expert Weighs In On Why Orbital Datacenters Could Likely Work In Tandem With Ground-Based AI Infrastructure
Space-based AI compute has been positioned by the tech industry as a solution to several challenges facing current Earth-based datacenter...
Wheaton Precious Metals Corp. (NYSE:WPM) Given Consensus Recommendation of “Moderate Buy” by Analysts
Shares of Wheaton Precious Metals Corp. (NYSE:WPM – Get Free Report) have earned an average recommendation of “Moderate Buy” from...
Prestige Consumer Healthcare (NYSE:PBH) Shares Gap Up – Time to Buy?
Prestige Consumer Healthcare Inc. (NYSE:PBH – Get Free Report)’s share price gapped up prior to trading on Friday . The stock had...
Phreesia (NYSE:PHR) Shares Gap Up – Time to Buy?
Shares of Phreesia, Inc. (NYSE:PHR – Get Free Report) gapped up before the market opened on Friday . The stock had previously closed at $11.77,...
Rhythm Pharmaceuticals (NASDAQ:RYTM) Shares Gap Up – Time to Buy?
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report)’s share price gapped up before the market opened on Friday . The stock had...
Syndax Pharmaceuticals (NASDAQ:SNDX) Reaches New 1-Year High – Still a Buy?
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Get Free Report)’s share price reached a new 52-week high on Friday . The company traded as...
Biohaven Ltd. (NYSE:BHVN) Given Average Recommendation of “Moderate Buy” by Brokerages
Biohaven Ltd. (NYSE:BHVN – Get Free Report) has earned an average recommendation of “Moderate Buy” from the seventeen brokerages...
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Given Average Rating of “Moderate Buy” by Brokerages
Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA – Get Free Report) have received a consensus rating of “Moderate Buy” from the...
McKesson Corporation (NYSE:MCK) Receives Consensus Recommendation of “Moderate Buy” from Analysts
McKesson Corporation (NYSE:MCK – Get Free Report) has been given a consensus rating of “Moderate Buy” by the seventeen ratings...
Vera Therapeutics, Inc. (NASDAQ:VERA) Given Average Recommendation of “Moderate Buy” by Brokerages
Shares of Vera Therapeutics, Inc. (NASDAQ:VERA – Get Free Report) have received a consensus recommendation of “Moderate Buy” from...
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Consensus Recommendation of “Moderate Buy” by Brokerages
Dianthus Therapeutics, Inc. (NASDAQ:DNTH – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the...
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Recommendation of “Moderate Buy” by Analysts
Zevra Therapeutics, Inc. (NASDAQ:ZVRA – Get Free Report) has received an average recommendation of “Moderate Buy” from the nine...
📰
2 Defensive Healthcare Stocks to Buy Right Now
These two stocks make fantastic long-term holdings.
📰
2 Defensive Healthcare Stocks to Buy Right Now
These two stocks make fantastic long-term holdings.
ProKidney Corp. (NASDAQ:PROK) Given Consensus Recommendation of “Moderate Buy” by Brokerages
Shares of ProKidney Corp. (NASDAQ:PROK – Get Free Report) have earned a consensus rating of “Moderate Buy” from the eight ratings...
AdaptHealth Corp. (NASDAQ:AHCO) Receives Consensus Rating of “Moderate Buy” from Analysts
AdaptHealth Corp. (NASDAQ:AHCO – Get Free Report) has been given an average rating of “Moderate Buy” by the six analysts that are...
The Pennant Group, Inc. (NASDAQ:PNTG) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Shares of The Pennant Group, Inc. (NASDAQ:PNTG – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy”...
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Consensus Recommendation of “Moderate Buy” from Brokerages
Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Free Report) have received a consensus recommendation of “Moderate Buy” from...
Terns Pharmaceuticals (NASDAQ:TERN) Reaches New 1-Year High – Should You Buy?
Terns Pharmaceuticals, Inc. (NASDAQ:TERN – Get Free Report) shares reached a new 52-week high during trading on Friday . The company traded as...
Oxford BioDynamics (LON:OBD) Stock Price Up 11.1% – Time to Buy?
Oxford BioDynamics Plc (LON:OBD – Get Free Report) shares traded up 11.1% during mid-day trading on Friday . The stock traded as high as GBX...
Enliven Therapeutics (NASDAQ:ELVN) Reaches New 1-Year High – Here’s Why
Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) hit a new 52-week high during mid-day trading on Friday . The stock traded...
Sanofi (NASDAQ:SNY) Upgraded at Sanford C. Bernstein
Sanford C. Bernstein upgraded shares of Sanofi (NASDAQ:SNY – Free Report) to a strong-buy rating in a research report sent to investors on...
Citigroup Forecasts Strong Price Appreciation for Merck & Co., Inc. (NYSE:MRK) Stock
Merck & Co., Inc. (NYSE:MRK – Get Free Report) had its price target boosted by Citigroup from $120.00 to $125.00 in a report issued on...
📰
This $6.5 Million Healthcare Trim Comes Amid a 71% Stock Surge and 20% Revenue Growth
This healthcare firm develops advanced surgical solutions for peripheral nerve repair, serving hospitals and specialists worldwide.
📰
This $8.9 Million Buy Targets a Stock Down 68% With $322 Million in Cash
Biohaven develops clinical-stage therapies for neurological and immunoscience disorders, with no commercialized products to date.
📰
This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story
This biotech firm develops therapies for rare, complement-driven diseases, with a focus on autoimmune and inflammatory conditions.
📰
This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch
Cogent Biosciences develops targeted therapies for genetically defined diseases, focusing on precision medicine for rare cancers.
📰
This Biotech Was Quietly Bought Before a $58 Per Share Takeout
This clinical-stage biotech develops oral therapies targeting cancer and inflammatory diseases, with lead candidates in active trials.
📰
Is This Stock a Buy on the Dip?
This company has a habit of beating the market over long periods.
📰
Is This Stock a Buy on the Dip?
This company has a habit of beating the market over long periods.